MacularDegeneration

 

A study has shown a potential link between calcium supplementation and macular degeneration, particularly in those older than 68 years.  

A UK government minister has ruled that it is illegal and against the wider public interest to use the cheaper drug bevacizumab (Avastin) to treat wet age related macular degeneration (AMD) instead of the more expensive ranibizumab (Lucentis).  

Patients in Bristol suffering from geographic atrophy can now enroll in the phase III clinical program for lampalizumab, a drug being investigated for this form of age-related macular...  

Researchers are optimistic that a stem cell treatment they successfully tested in rats will slow or reverse the effects of early-stage age-related macular degeneration in humans.  

An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.  

NHS doctors should be allowed to prescribe a cheap, safe and effective drug for the degenerative eye disease, wet age related macular degeneration (AMD) - a leading cause of blindness among...  

The U.S. Food and Drug Administration has expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema.  

Review question: We assessed the role of macular grid laser (laser performed in a grid pattern) compared to other new treatments.  

Although cataract is a common cause of gradual vision loss in older patients, consider other treatable red flag conditions in this age group, such as giant cell arteritis, macular degeneration, retinal detachment, and vitreous haemorrhage, and refer urgently if you suspect these  

Results from Navina, HARBOR, and Protocol T, to be presented at the conference, are expected to provide insight into treatments for diabetic macular edema and age-related macular degeneration.  

In patients with neovascular AMD, pigment epithelial detachment and intraretinal cysts are more important biomarkers of vision loss than subretinal fluid, researchers report.  

Pretreatment with the anti-PDGF pegpleranib increases the effectiveness of anti-VEGF therapy, according to a small pilot study,